



January 15, 2025

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice regarding Sponsored Research on an Intranasal Formulation of an Improved DNA Vaccine

AnGes Inc. announces that it has developed a new Drug Delivery System (DDS)* applicable to DNA vaccines for viral lung diseases, including novel coronavirus infections, as a result of sponsored research with Stanford Medicine ("Stanford") on an intranasal formulation of an improved DNA vaccine, which was announced on September 7, 2022.

AnGes has combined the "Gold-Nanostar Octopod" technology developed by Dr. Ramasamy Paulmurugan and Dr. Tarik Massoud, professors at Stanford University School of Medicine, with AnGes' DNA vaccine technology to develop an intranasal formulation of an improved DNA vaccine against viral lung diseases including new coronavirus infection. For more than two years, we have been conducting sponsored research on an intranasal formulation of an improved DNA vaccine that is expected to stimulate a broad immune response against viral lung diseases, including new coronavirus infections, and to prevent the multiplication and spread of the virus.

As a result, we have succeeded in developing a new DDS that is an excellent technology for intranasal administration of improved DNA vaccines. The new DDS does not use lipid nanoparticles (LNPs) and is expected to be a method of vaccine administration with fewer side effects.

In light of the current situation where the pandemic caused by the novel coronavirus is subsiding, we have decided to suspend the development of an improved DNA vaccine using the results of this research for the time being in terms of effective utilization of our management resources. In addition, the joint research with Stanford University on an intranasal formulation of an improved DNA vaccine will be terminated since the initial goal has been achieved. In the future, we will be prepared to use the new DDS obtained as a result of this joint research to promptly develop new vaccines in the event of a new viral lung disease or other pandemic. In addition, we will consider the use of this DDS for drug development in the future.

The termination of this sponsored research will have no impact on our consolidated business performance and financial position for the current fiscal year. We will promptly disclose any event that should arise in the future.

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



* Drug Delivery System : DDS

Technology that allows the body to deliver the required amount of drug to the desired site at the appropriate time and rate to maximize the drug's effectiveness and minimize side effects, while also reducing the dosage of medication.

AnGes, Inc.
Public Relations & Investor Relations Group
<https://www.anges.co.jp/en/>

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.